The FDA approved Mounjaro for cardiovascular risk reduction, making it the first dual GIP/GLP-1 agonist with this indication. Here's what Brazilian patients should know about this milestone and what it means for future access.
The Big Picture: Why a Heart Indication for a Diabetes and Weight Loss Drug Matters
Cardiovascular disease remains the leading cause of death in Brazil and worldwide. According to the Brazilian Ministry of Health, heart conditions account for a significant portion of mortality in the country, making any medication that reduces cardiovascular risk a topic of considerable public health interest. Until recently, only two GLP-1 drugs carried FDA approval specifically for cardiovascular risk reduction: liraglutide and semaglutide. Both belong to the single-hormone agonist family.
In October 2024, the FDA made a landmark decision by approving tirzepatide, marketed as Mounjaro, for reducing cardiovascular risk in adults with established heart disease. This approval marked the first time a dual GIP/GLP-1 receptor agonist received this specific indication, opening a new chapter in how healthcare providers approach cardiovascular protection alongside diabetes and weight management.
Mounjaro works differently from its predecessors because it mimics not one but two hormones: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This dual mechanism sets it apart in the GLP-1 class and was the foundation for its newly approved cardiac indication.
What the SURPASS-CV OUTCOMES Trial Actually Found
The clinical evidence supporting this approval comes from the SURPASS-CV OUTCOMES trial, which enrolled over 13,000 adults with type 2 diabetes and established cardiovascular disease. Every participant in the study already had a prior heart event or diagnosed heart condition, making the results particularly relevant for high-risk patients.
Participants receiving tirzepatide experienced a statistically significant reduction in major adverse cardiovascular events (MACE), which includes heart attack, stroke, and cardiovascular death. The trial demonstrated that tirzepatide reduced the risk of MACE by approximately 20% compared to placebo, with benefits observed regardless of whether patients were taking standard heart medications like statins or blood pressure drugs. This suggests tirzepatide provided independent cardiovascular protection on top of existing therapies.
The magnitude of cardiovascular benefit was comparable to what had been seen in earlier trials for other GLP-1 drugs, but notably was achieved alongside substantial improvements in glycemic control and significant body weight reduction. Patients in the trial saw average HbA1c reductions exceeding 2 percentage points alongside their cardiovascular improvements.
Why Mounjaro's Dual Mechanism May Make a Difference for Heart Health
Mounjaro is the first and only approved dual GIP/GLP-1 receptor agonist available today. It activates both the GIP receptor and the GLP-1 receptor simultaneously, creating a pharmacological profile that differs meaningfully from single-receptor agonists.
Research suggests that GIP receptor activation plays a role in regulating fat metabolism and inflammation, both key drivers of atherosclerosis and plaque buildup in arteries. By combining this effect with GLP-1 receptor activation, tirzepatide addresses multiple pathways involved in cardiovascular disease progression.
Clinical trials showed average body weight reductions exceeding 20% of initial body weight in many participants, which tackles one of the most significant underlying risk factors for heart disease. Obesity increases blood pressure, promotes insulin resistance, and triggers chronic inflammation—all contributors to cardiovascular damage. The combination of improved glycemic control, sustained weight loss, and potential direct anti-inflammatory effects appears to create a multi-pathway protective effect on the cardiovascular system.
What This FDA Approval Means for Brazilian Patients Right Now
Brazilian patients cannot currently purchase Mounjaro at their local pharmacies. The drug has not yet received ANVISA approval, meaning it is not legally available for commercial sale in Brazil. ANVISA has been conducting its own review process for tirzepatide, and approval timelines for innovative drugs in Brazil typically follow FDA decisions by 12 to 24 months, though exact timelines can vary based on regulatory workload and priority assessments.
Physicians in Brazil can already prescribe GLP-1 medications off-label when available, and the specific cardiovascular indication adds a new layer of clinical justification that Brazilian cardiologists and endocrinologists are watching closely. The new data strengthens the case for considering dual agonists in patients with both diabetes and established heart disease.
For patients currently using Ozempic (semaglutide) or Yluméc, the question becomes whether and when a switch to tirzepatide would be appropriate based on the new cardiovascular evidence. This decision should only be made in consultation with a healthcare provider who understands the patient's complete medical history and current treatment regimen. Stay updated on developments regarding tirzepatide access in Brazil by following OzemNews for the latest coverage.
Comparing Cardiovascular Indications: Mounjaro, Ozempic, and Wegovy Side by Side
Wegovy (semaglutide 2.4 mg) received FDA approval to reduce cardiovascular risk in adults with obesity or overweight with cardiovascular disease based on the SELECT trial, which enrolled patients without diabetes. Ozempic (semaglutide 0.5 mg and 1 mg) carries a cardiovascular indication for reducing risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
Mounjaro's indication specifically covers adults with type 2 diabetes AND established cardiovascular disease—a patient population similar to Ozempic's, but with tirzepatide's superior metabolic results. The practical difference for Brazilian patients comes down to what is actually accessible in the country. Currently, Ozempic and Yluméc are available through ANVISA-approved channels, while Mounjaro awaits its registration. For more detailed comparisons between these medications, visit OzemNews.
Who Could Benefit Most from This Indication, and What to Discuss with Your Doctor
The most likely candidates for future Mounjaro treatment based on the cardiovascular indication are adults with type 2 diabetes who also have a documented history of heart attack, stroke, coronary artery disease, or peripheral artery disease. These patients face the highest absolute risk of recurrent cardiovascular events and would potentially derive the greatest benefit from cardioprotective therapy.
Patients with multiple cardiovascular risk factors—such as high blood pressure, high cholesterol, obesity, and smoking history—may also be strong candidates even if they have not yet experienced a formal cardiac event. The presence of multiple risk factors compounds overall cardiovascular risk substantially.
Brazilian patients already on Ozempic or Yluméc should not stop or switch therapy without consulting their physician. Abrupt changes to diabetes or weight management medications can destabilize blood sugar control and other metabolic parameters. Any decisions about treatment modification should involve a thorough discussion of the new evidence, individual risk profile, and practical considerations like medication availability and cost.
FAQ
When will Mounjaro be available in Brazil?
Currently, Mounjaro has not received ANVISA approval and is not available for commercial sale in Brazil. Regulatory approval timelines typically follow FDA decisions by 12 to 24 months, but exact timelines vary for each medication.
What is the difference between Mounjaro and Ozempic for heart health?
Both medications have FDA approval for cardiovascular risk reduction, but Mounjaro (tirzepatide) works as a dual GIP/GLP-1 agonist while Ozempic (semaglutide) only targets the GLP-1 receptor. Clinical trials suggest tirzepatide may provide superior metabolic benefits alongside comparable cardiovascular protection.
Can Brazilian doctors prescribe Mounjaro now?
Since Mounjaro is not ANVISA-approved in Brazil, it cannot be prescribed through legal commercial channels. Doctors can prescribe available GLP-1 medications off-label when they are accessible, but prescribing unregistered medications involves regulatory considerations.
Who should consider tirzepatide based on the new cardiovascular indication?
Adults with type 2 diabetes and established cardiovascular disease—such as prior heart attack, stroke, or coronary artery disease—are the primary candidates for tirzepatide therapy based on the cardiovascular indication. A healthcare provider can determine individual suitability.
Sources
- FDA Approves Novel Therapeutic for Patients with Heart Disease Related to Diabetes or Obesity
- Tirzepatide Reduces Risk of Cardiovascular Events in Adults with Type 2 Diabetes and Obesity
- Tirzepatide and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
Disclaimer: This content is for informational purposes only and does not replace professional medical advice. Always consult your doctor before starting, changing or stopping any treatment.
Ozempro — Monitor GLP-1
Track your weight and your progress
Log weight, measurements and labs and see your progress in clear charts — because progress you don't measure is invisible progress.
or download the app
